Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2005-09-02
2010-02-23
Blanchard, David J. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S141100, C424S156100, C424S179100, C424S181100, C435S069600, C435S070210, C435S449000, C530S387300, C530S388100, C530S391500, C530S391700
Reexamination Certificate
active
07666414
ABSTRACT:
Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.
REFERENCES:
patent: 5120525 (1992-06-01), Goldenberg
patent: 5530101 (1996-06-01), Queen et al.
patent: 5621001 (1997-04-01), Canetta et al.
patent: 6107090 (2000-08-01), Bander
patent: 6972324 (2005-12-01), Adolf et al.
patent: WO 98/52976 (1998-11-01), None
patent: WO 00/34317 (2000-06-01), None
patent: WO 02/098897 (2002-12-01), None
patent: WO 2004/098535 (2004-11-01), None
William E. Paul. Fundamental Immunology, 3rd ed., pp. 242, 292-295 1993.
Rudikoff et al. Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, Mar. 1982.
Colman P. M. Research in Immunology, 145:33-36, 1994.
Bendig M. M. Methods: A Companion to Methods in Enzymology, 8:83-93, 1995.
MacCallum et al. J. Mol. Biol., 262, 732-745, 1996.
Casset et al. Biochemical and Biophysical Research Communications, 307:198-205, 2003.
Gura T. Science, 278:1041-1042, Nov. 7, 1997.
Jain R. K. Scientific American, pp. 58-65, Jul. 1994.
Dillman (Annals of Internal Medicine, 111:592-603, 1989.
Weiner G. Seminars Oncology, 26(4):41-50, 1999.
Forni et al. Cancer Research, 60; 2571-2575, 2000.
Alvarez et al. Gynecologic Oncology, 65(1):94-101, Apr. 1997.
Common Toxicity Criteria, version 2.0. National Cancer Institute, Cancer Therapy Evaluation Program, pp. 1-27, Jun. 1, 1999.
Liu, C. et al, “Eradication of large colon tumor xenografts by targeted delivery of maytansinoids”,Proc. Natl. Acad. Sci., USA, vol. 93, pp. 8618-8623, (1996).
Smith, S., “Technology evaluation: C242-DM1, ImmunoGen Inc”, current opinion inMolecular Therapeutics, vol. 3, No. 2 pp. 198-203 (2001).
Blanchard David J.
Cornell Research Foundation Inc.
Proskauer Rose LLP
LandOfFree
Methods for treating prostate cancer using modified... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating prostate cancer using modified..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating prostate cancer using modified... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4182231